Dried flower 22 percent: how to match potency to the patient and why titration is necessary

What does the number 22 percent on the dried flower label describe?

The number describes the raw material, not the patient's dose. The manufacturer declares how much tetrahydrocannabinol is contained in one hundred grams of dried flower after heating, and presents it as a single nominal value with an allowable deviation. This number does not indicate how much substance will enter the bloodstream or how a specific person will react to it.

In the dried flower, the compound mainly exists in the acidic form, which does not act the same way as the form that arises after heating. Only heating cleaves the carboxyl group and converts it into the active form, so the manufacturer's declaration refers to the content after this transformation, not to what is visible in the cold raw material. The difference between the declaration and laboratory measurement is further developed. osobna strona o suszu dwudziestoprocentowym.

The declaration of 22 percent is not a measurement of a specific batch. With an allowable deviation, the THC content in such a position falls within the range of 19.8-24.2%, meaning the round number in the name is the midpoint of the range, not a laboratory reading.

This page does not list any items from the offer. The composition of the register changes from month to month, as permits expire and deliveries may be suspended, so the current list of strains available in pharmacies is maintained by a cluster strain hub.

How is the potency of dried flower selected for a specific patient?

This is determined by the attending physician, not the number on the package. The selection involves titration: the patient starts with a small dose, observes the body's response, and the doctor adjusts the exposure only after this observation. The declared percentage is one of the inputs in this process, not its goal or outcome.

Titration is a gradual approach to the smallest exposure that provides the expected relief. Between successive steps, enough time is left for the previous step to show its full effect, as an assessment made too early only describes the beginning of the response. The size of the step matters less than whether the patient can notice that the previous one was sufficient.

The reason this cannot be skipped lies with the patient, not the raw material. Absorption, the rate of liver metabolism, the density of cannabinoid receptors, and concurrently taken medications vary among individuals to such an extent that the same dose of the same dried flower results in different concentrations in the blood and different sensations. None of these factors are visible on the label.

The declared percentage indicates how much active substance is contained in a unit of mass of the raw material, not how much will reach the bloodstream. The route of administration, inhalation technique, and losses on the device shift this value downward in a way that no one measures with the patient. Thus, two people using the same package encounter different exposures, and titration leads them to different outcomes.

Why does treatment start with a small dose?

Because no one knows how this patient will react before the first attempt. A too large initial exposure can cause symptoms that would not occur with a smaller dose, and it eliminates the possibility of checking whether a smaller exposure was already sufficient. The order is irreversible: it is easier to add more the next day than to reverse an unpleasant episode.

The asymmetry of costs is evident. A dose that is too small costs a day or two of delay, as the next step will still occur. A dose that is too large costs an unpleasant episode, sometimes one that leads the patient to discontinue treatment altogether. Side effects occur at exposures lower than the point at which relief stops increasing, so starting from the bottom, one encounters them earlier and more gently.

The second reason is a reserve for the future. The body's response weakens with repeated exposure, so a patient who starts high reaches the limit sooner, beyond which there is nowhere else to go. The smallest sufficient exposure is not a saving, but a way to ensure that treatment has a reserve for the coming months.

The rate of assessment is determined by the route of administration, not the percentage on the label. After vaporization, the response is fully apparent within the same session, while after ingestion, it only becomes apparent after hours, and this difference determines how densely one can proceed with subsequent steps.

What is tolerance and why does it change the meaning of the same number?

Tolerance is the weakening of the response to repeated exposure of the same magnitude. It is not a property of the dried flower, but of the body, so the number on the label remains constant, while what the patient feels after the same dose changes over the course of treatment. Thus, the same number means something different at the beginning and after a year.

The mechanism is described on the receptor side. Regular exposure decreases the density and sensitivity of type one cannabinoid receptors, so the same amount of substance encounters fewer sites where it can act, and the response is weaker. After a break in administration, the receptors return, which is why tolerance is reversible, although the rate of return can vary among individuals.

The effect pertains precisely to that number. For a person who is just starting, dried flower with a content of 22 percent may be the upper limit of what they can tolerate without side effects. For a patient who has been treated for a year, the same position may be a regular working level from which the conversation about change begins. The label does not carry this information and cannot carry it, as it describes the raw material, not the treatment history.

The word tolerance appears in this topic in two meanings and it is better to separate them. Manufacturer tolerance is the permissible deviation of the declaration, which is a matter of measuring the raw material. Body tolerance is the diminishing response, which is a matter of the patient's physiology. The overlap of declaration ranges is addressed. osobna strona o suszu osiemnastoprocentowym.

Does the declared percentage change the onset of action and its duration?

No. The declared percentage changes how much substance is contained in a dose of a given mass, not when the action begins and how long it lasts. The course is determined by the route of administration, the same for weaker and stronger raw materials, so changing to a stronger position does not shift the clock.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

For titration, this results in a practical limit. The step must be assessed within the appropriate window for the chosen route, otherwise the assessment pertains to something different than what it was meant to measure. With oral administration, a premature conclusion about a lack of effect can lead to unpleasant episodes in the first days of treatment, and it is this, not the potency of the raw material, that requires correction.

What is known, and what is not known about the relationship between the potency of the raw material and the effect?

What is mainly known is what potency does in an unfavorable direction. The evidence collected for higher concentrations primarily concerns psychosis, addiction, and non-medical use, while studies on therapeutic applications are few and contradictory. The certainty of these findings is often assessed by the authors themselves as very low.

The discrepancy between these studies is information, not a flaw. A review published in 2025 in Annals of Internal Medicine (PMID:40854216) found among studies on therapeutic applications nearly half of the papers indicating benefits for anxiety and depression, but some of the same papers simultaneously described negative associations, and over 95 percent of the included material had moderate or high risk of systematic error.

However, none of these studies tells the doctor which potency to choose for which patient. All compare groups of people using weaker and stronger products, not two pharmaceutical items differing only in declaration. Hence the role of titration: in the absence of conclusive data on potency selection, the only available method remains careful observation of the individual patient.

The very division of potency into categories used in the literature is discussed. the page about twenty-five percent dried flower, and the increase in concentrations in subsequent years strona o suszu trzydziestoprocentowym.

What adverse effects are associated with higher potency raw material?

For a specific percentage threshold, such data is not available. Reports are collected for the product with the serial number, not for the potency range, and available reviews compare groups of users, not pharmaceutical items. It is known, however, that it is the side effects that practically determine the boundary for the next step.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

In titration, these symptoms serve as feedback signals. Their occurrence after increasing the dose means that the step was too large for this patient at this moment in treatment, not that the dried flower is defective. The decision to revert the step, take a break, or change the position belongs to the attending physician. The relationship between potency and the frequency of these symptoms is further developed. osobna strona o suszu dwudziestosiedmioprocentowym.

Who decides on the selection of potency in specific treatment?

The attending physician. Cannabis flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, so whether a product with 22 percent potency will be included in a given treatment is determined by the prescription written after examination, not by the patient's choice or the description on the website.

This page explains the mechanism and ends there. It will not provide the number of grams, number of inhalations, or breakdown per day, as such a determination requires knowledge of the diagnosis, accompanying diseases, and other medications taken, which no informational text knows. Changing to a stronger product independently bypasses exactly this knowledge.

It is also worth distinguishing between two shelves with similar names. Prescription cannabis flower is different from over-the-counter cannabis flower, in which the tetrahydrocannabinol content does not exceed the legal threshold and which is collected in the store separately. dried flower category. The number from this page refers exclusively to this first shelf.

Choosing the strength does not end with just one selection. During treatment, both the patient and the therapy goal change, so a position chosen six months earlier may be reassessed in conversation with the doctor, rather than by comparing numbers from two labels.

Frequently Asked Questions

Does a higher declared percentage mean stronger therapeutic effects?

It has not been shown that a higher declared percentage on the label indicates stronger or better therapeutic effects. The evidence regarding the potency of the raw material pertains almost exclusively to adverse effects and non-medical use, not efficacy, and studies on therapeutic applications are few and yield mixed results. The authors of both of the latest reviews assessed the certainty of evidence as very low. There is also no study that compared two pharmaceutical dried flowers differing only in declared content.

What does titration involve with pharmaceutical dried flower?

It involves a gradual approach to the lowest exposure that provides the expected relief. The patient starts with a small dose and only increases it when the previous step has shown its full effect. The pace and size of the steps are determined by the attending physician, as they depend on the diagnosis and other medications being taken.

Why does the same number mean something different for a person who has been treated for a year?

Because the body's response to repeated exposure weakens. Regular use decreases the density and sensitivity of cannabinoid receptors, so the same dose produces a weaker effect than at the beginning of treatment. The label describes the raw material and does not change with the patient's history.

Is the manufacturer's tolerance and the body's tolerance the same thing?

No. Manufacturer's tolerance refers to the allowable deviation from the declared value, which is a matter of measuring the raw material. The body's tolerance refers to the diminishing response to repeated exposure, which is a matter of the patient's physiology. Both meanings are often confused, although they refer to completely different things.

Can a patient change to a stronger dried flower on their own?

Not on their own. Hemp dried flower is dispensed by prescription from a doctor, so switching to a different declaration requires a prescription and a conversation with the attending physician. A change made independently bypasses the assessment of accompanying diseases and other medications being taken.

Where can I check which products of this strength are currently available?

In the variety cluster hub, which collects the current list of raw materials available in Polish pharmacies. The composition of the register changes over time, as permits expire and deliveries may be suspended, so the list included in this article would become outdated faster than it could be corrected.

Hemp dried flower is a pharmaceutical raw material dispensed by prescription from a doctor in the Rpw category. The material is for informational purposes only and does not replace medical advice or the recommendations of the attending physician. The editorial text was prepared by redakcja ubucha.pl.